<DOC>
	<DOCNO>NCT00906685</DOCNO>
	<brief_summary>Central retinal vein occlusion lead cause severe visual impairment . Until , treatment available improve visual acuity . The present study intend investigate intravitreal bevacizumab improve visual acuity compare sham-treated control patient .</brief_summary>
	<brief_title>Bevacizumab Central Retinal Vein Occlusion Study</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>CRVO duration &lt; 6 month Visual acuity 20/800 20/50 CRVO duration &gt; 6 month previous treatment antiangiogenic drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>CRVO</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>Macular edema</keyword>
</DOC>